Cargando…

Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study

Heart failure (HF) represents a widespread health problem characterized by high morbidity and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients affected by HF with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the effectiveness and durab...

Descripción completa

Detalles Bibliográficos
Autores principales: Armentaro, Giuseppe, D’Arrigo, Graziella, Magurno, Marcello, Toscani, Alfredo F., Condoleo, Valentino, Miceli, Sofia, Cassano, Velia, Maio, Raffaele, Arturi, Franco, Tripepi, Giovanni, Sesti, Giorgio, Sciacqua, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415264/
https://www.ncbi.nlm.nih.gov/pubmed/34483943
http://dx.doi.org/10.3389/fphar.2021.733475
_version_ 1783747933592616960
author Armentaro, Giuseppe
D’Arrigo, Graziella
Magurno, Marcello
Toscani, Alfredo F.
Condoleo, Valentino
Miceli, Sofia
Cassano, Velia
Maio, Raffaele
Arturi, Franco
Tripepi, Giovanni
Sesti, Giorgio
Sciacqua, Angela
author_facet Armentaro, Giuseppe
D’Arrigo, Graziella
Magurno, Marcello
Toscani, Alfredo F.
Condoleo, Valentino
Miceli, Sofia
Cassano, Velia
Maio, Raffaele
Arturi, Franco
Tripepi, Giovanni
Sesti, Giorgio
Sciacqua, Angela
author_sort Armentaro, Giuseppe
collection PubMed
description Heart failure (HF) represents a widespread health problem characterized by high morbidity and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients affected by HF with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the effectiveness and durability of sac/val treatment on the clinical, hemodynamic and echocardiographic parameters, in real-life consecutive HFrEF outpatients, evaluated up to 2-years of follow-up. We collected 300 repeated observations over time in 60 patients suffering of HFrEF and symptomatic despite optimal drug therapy. Patients with left ventricular ejection fraction (LVEF) <35 and II-III NYHA functional class were considered. All patients underwent to clinical-instrumental and laboratory determinations and Minnesota Living with HF Questionnaire (MLHFQ) every 6 months until 24 months to evaluate possible clinical benefits and adverse events. During a 2-year follow-up period and through a 6-monthly control of the study variables both clinical, hemodynamic, biochemical and echocardiographic parameters significantly improved, in particular cardiac index (CI), both atrial and ventricular volumes and global longitudinal strain (GLS). Furthermore, there was a reduction of NT-proBNP levels and betterment of renal function and NYHA functional class, demonstrating the efficacy and durability of sac/val treatment. In a multiple linear mixed model the longitudinal evolutions of CI were associated to concomitant changes of GLS and E/e’ ratio. Our study, contemplating the collection of 300 repeated observations in 60 patients, provides a complete and detailed demonstration of sac/val effects, showing effectiveness, safety and effect durability of the treatment every 6 months up to 2-years of follow-up with significant improvement of several clinical, hemodynamic and echocardiographic parameters in HFrEF outpatients.
format Online
Article
Text
id pubmed-8415264
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84152642021-09-04 Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study Armentaro, Giuseppe D’Arrigo, Graziella Magurno, Marcello Toscani, Alfredo F. Condoleo, Valentino Miceli, Sofia Cassano, Velia Maio, Raffaele Arturi, Franco Tripepi, Giovanni Sesti, Giorgio Sciacqua, Angela Front Pharmacol Pharmacology Heart failure (HF) represents a widespread health problem characterized by high morbidity and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients affected by HF with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the effectiveness and durability of sac/val treatment on the clinical, hemodynamic and echocardiographic parameters, in real-life consecutive HFrEF outpatients, evaluated up to 2-years of follow-up. We collected 300 repeated observations over time in 60 patients suffering of HFrEF and symptomatic despite optimal drug therapy. Patients with left ventricular ejection fraction (LVEF) <35 and II-III NYHA functional class were considered. All patients underwent to clinical-instrumental and laboratory determinations and Minnesota Living with HF Questionnaire (MLHFQ) every 6 months until 24 months to evaluate possible clinical benefits and adverse events. During a 2-year follow-up period and through a 6-monthly control of the study variables both clinical, hemodynamic, biochemical and echocardiographic parameters significantly improved, in particular cardiac index (CI), both atrial and ventricular volumes and global longitudinal strain (GLS). Furthermore, there was a reduction of NT-proBNP levels and betterment of renal function and NYHA functional class, demonstrating the efficacy and durability of sac/val treatment. In a multiple linear mixed model the longitudinal evolutions of CI were associated to concomitant changes of GLS and E/e’ ratio. Our study, contemplating the collection of 300 repeated observations in 60 patients, provides a complete and detailed demonstration of sac/val effects, showing effectiveness, safety and effect durability of the treatment every 6 months up to 2-years of follow-up with significant improvement of several clinical, hemodynamic and echocardiographic parameters in HFrEF outpatients. Frontiers Media S.A. 2021-08-16 /pmc/articles/PMC8415264/ /pubmed/34483943 http://dx.doi.org/10.3389/fphar.2021.733475 Text en Copyright © 2021 Armentaro, D’Arrigo, Magurno, Toscani, Condoleo, Miceli, Cassano, Maio, Arturi, Tripepi, Sesti and Sciacqua. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Armentaro, Giuseppe
D’Arrigo, Graziella
Magurno, Marcello
Toscani, Alfredo F.
Condoleo, Valentino
Miceli, Sofia
Cassano, Velia
Maio, Raffaele
Arturi, Franco
Tripepi, Giovanni
Sesti, Giorgio
Sciacqua, Angela
Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study
title Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study
title_full Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study
title_fullStr Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study
title_full_unstemmed Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study
title_short Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study
title_sort impact of sacubitril/valsartan on clinical and echocardiographic parameters in heart failure patients with reduced ejection fraction: data from a real life 2-year follow-up study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415264/
https://www.ncbi.nlm.nih.gov/pubmed/34483943
http://dx.doi.org/10.3389/fphar.2021.733475
work_keys_str_mv AT armentarogiuseppe impactofsacubitrilvalsartanonclinicalandechocardiographicparametersinheartfailurepatientswithreducedejectionfractiondatafromareallife2yearfollowupstudy
AT darrigograziella impactofsacubitrilvalsartanonclinicalandechocardiographicparametersinheartfailurepatientswithreducedejectionfractiondatafromareallife2yearfollowupstudy
AT magurnomarcello impactofsacubitrilvalsartanonclinicalandechocardiographicparametersinheartfailurepatientswithreducedejectionfractiondatafromareallife2yearfollowupstudy
AT toscanialfredof impactofsacubitrilvalsartanonclinicalandechocardiographicparametersinheartfailurepatientswithreducedejectionfractiondatafromareallife2yearfollowupstudy
AT condoleovalentino impactofsacubitrilvalsartanonclinicalandechocardiographicparametersinheartfailurepatientswithreducedejectionfractiondatafromareallife2yearfollowupstudy
AT micelisofia impactofsacubitrilvalsartanonclinicalandechocardiographicparametersinheartfailurepatientswithreducedejectionfractiondatafromareallife2yearfollowupstudy
AT cassanovelia impactofsacubitrilvalsartanonclinicalandechocardiographicparametersinheartfailurepatientswithreducedejectionfractiondatafromareallife2yearfollowupstudy
AT maioraffaele impactofsacubitrilvalsartanonclinicalandechocardiographicparametersinheartfailurepatientswithreducedejectionfractiondatafromareallife2yearfollowupstudy
AT arturifranco impactofsacubitrilvalsartanonclinicalandechocardiographicparametersinheartfailurepatientswithreducedejectionfractiondatafromareallife2yearfollowupstudy
AT tripepigiovanni impactofsacubitrilvalsartanonclinicalandechocardiographicparametersinheartfailurepatientswithreducedejectionfractiondatafromareallife2yearfollowupstudy
AT sestigiorgio impactofsacubitrilvalsartanonclinicalandechocardiographicparametersinheartfailurepatientswithreducedejectionfractiondatafromareallife2yearfollowupstudy
AT sciacquaangela impactofsacubitrilvalsartanonclinicalandechocardiographicparametersinheartfailurepatientswithreducedejectionfractiondatafromareallife2yearfollowupstudy